Skip to main content

Table 2 Completed phase III clinical trials of targeted therapies for advanced GCs

From: Emerging molecular classifications and therapeutic implications for gastric cancer

Target Clinical trial Inhibitor Combination treatment No. of cases Primary endpoint Reference
HER2 ToGA Trastuzumab Capecitabine/5-fluorouracil + cisplatin 594 OS (13.8 months) [36]
TyTAN Lapatinib Paclitaxel 261 OS (11 months) [37]
EGFR EXPAND Cetuximab Capecitabine/capecitabine + cisplatin 904 PFS (4.4 months) [38]
REAL-3 Panitumumab Best supportive care 463 PFS (2 months) [39]
VEGFR AVAGAST Bevacizumab Capecitabine + cisplatin 774 OS (12.1 months) [40]
REGARD Ramucirumab Best supportive care 355 PFS (5.2 months) [41]
  1. HER2 erb-b2 receptor tyrosine kinase 2, EGFR epidermal growth factor receptor, VEGFR vascular endothelial growth factor receptor, OS overall survival, PFS progression-free survival